TG Therapeutics (TGTX) said Tuesday that it expects Q4 Briumvi US net product revenue of $103.6 million.
The company said its cash position at the end of 2024 was $310 million.
TG Therapeutics said it expects 2025 total global revenue of $540 million, including Briumvi US net product revenue of $525 million. Analysts polled by Capital IQ are looking for total revenue of $537.8 million.
Shares of the company were up more than 5% in recent premarket activity.
Price: 29.16, Change: +1.49, Percent Change: +5.38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.